---
schema_version: "secwatch.filing_event.v1"
accession: "0000081061-26-000059"
form_type: "8-K"
ticker: null
cik: "0000081061"
company_name: "PUBLIX SUPER MARKETS INC"
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:27:59.597949+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Publix Q1 net earnings down 21.5% to $794M; stock price raised to $20.45

## Summary
- Sales $16.1B, up 2% YoY; comparable store sales unchanged.
- Net earnings $794M (-21.5% YoY); EPS $0.25 vs $0.31 (2025).
- Excluding unrealized losses, adjusted EPS $0.36 in both quarters.
- Sales growth slowed by Medicare MFP change on 10 drugs effective Jan 2026.
- Stock price increased from $19.65 to $20.45 per share effective May 1, 2026.

## SEC filing metadata
- accession: 0000081061-26-000059
- form_type: 8-K
- cik: 0000081061
- company_name: PUBLIX SUPER MARKETS INC
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/81061/000008106126000059/0000081061-26-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/81061/000008106126000059/ck0000081061-20260501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000081061-26-000059
- JSON: https://secwatch.observer/filing/0000081061-26-000059.json
- Plain text: https://secwatch.observer/filing/0000081061-26-000059.txt

## Key facts
- Earnings Releases
  PUBLIX SUPER MARKETS INC reported the three months ended March 28, 2026 results: revenue $16.1 billion, net income $794 million, EPS $0.25 per share.
  - Period: the three months ended March 28, 2026
  - Revenue: $16.1 billion
  - Net income: $794 million
  - EPS: $0.25 per share
  - Result: reported results
  source text: Publix’s sales for the three months ended March 28, 2026 were $16.1 billion, a 2% increase from $15.8 billion in 2025. The increase in sales for the three months ended March 28, 2026 compared to the three months ended March 29, 2025 was lower due to the impact of the Medicare maximum fair price (MFP) change effective January 1, 2026 which reduced drug prices for 10 drugs. The impact of the MFP change resulted in a decrease in sales. Comparable store sales for the three months ended March 28, 2026 remained unchanged. Net earnings for the three months ended March 28, 2026 were $794 million, compared to $1 billion in 2025, a decrease of 21.5%. Earnings per share for the three months ended March 28, 2026 decreased to $0.25 per share, down from $0.31 per share in 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/81061/000008106126000059/0000081061-26-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.